Valuation: Astellas Pharma Inc.

Market Cap 4,143B 25.95B 22.42B 21.07B 19.18B 36.05B 2,483B 36.64B 245B 96.73B 1,244B 97.47B 95.35B P/E 2027 *
11.2x
P/E 2028 * 11.9x
Enterprise Value 4,101B 25.68B 22.19B 20.85B 18.99B 35.69B 2,458B 36.27B 243B 95.76B 1,232B 96.49B 94.39B EV / Sales 2027 *
1.77x
EV / Sales 2028 * 1.73x
Free-Float
98.88%
Yield 2027 *
3.47%
Yield 2028 * 3.59%
1 day-3.80%
1 week+2.01%
Current month+3.05%
1 month+11.15%
3 months-3.18%
6 months-7.46%
Current year+15.41%
1 week 13.45
Extreme 13.45
16.15
1 month 12.85
Extreme 12.85
16.15
Current year 11.95
Extreme 11.95
17.85
1 year 9.85
Extreme 9.848
17.85
3 years 8.4
Extreme 8.405
17.85
5 years 8.4
Extreme 8.405
17.95
10 years 8.4
Extreme 8.405
18.11
Manager TitleAgeSince
Chief Executive Officer 63 10/02/2023
Director of Finance/CFO 54 01/11/2023
Compliance Officer - 01/04/2025
Director TitleAgeSince
Chairman 66 10/02/2023
Director/Board Member 63 01/06/2019
Director/Board Member 58 01/06/2023
Change 5-day change 1-year change 3-year change Capi.($)
-3.80%+2.01% - - 25.69B
+3.60%-0.50%+74.80%+127.97% 1,055B
+3.33%+3.55%+53.48%+55.80% 632B
+3.43%+4.42%+25.27%+72.59% 442B
+1.35%-3.27%+40.98%+39.91% 351B
+1.75%-0.98%+26.20%+39.73% 290B
+2.13%-1.53%+1.85%+9.40% 243B
+1.41%+1.94%+43.45%+61.18% 227B
+1.35%-3.20%-9.07%-53.51% 200B
+3.25%+7.80%+21.18%+87.50% 172B
Average +1.07%-1.44%+30.90%+48.95% 401.39B
Weighted average by Cap. +1.26%-1.87%+43.73%+68.76%

Financials

2027 *2028 *
Net sales 2,315B 14.5B 12.53B 11.77B 10.72B 20.15B 1,388B 20.48B 137B 54.07B 695B 54.48B 53.29B 2,137B 13.38B 11.56B 10.86B 9.89B 18.59B 1,280B 18.9B 127B 49.89B 642B 50.27B 49.17B
Net income 356B 2.23B 1.93B 1.81B 1.65B 3.1B 213B 3.15B 21.09B 8.31B 107B 8.37B 8.19B 333B 2.08B 1.8B 1.69B 1.54B 2.89B 199B 2.94B 19.71B 7.77B 99.88B 7.82B 7.65B
Net Debt -41.87B -262M -227M -213M -194M -364M -25.09B -370M -2.48B -978M -12.58B -985M -964M -439B -2.75B -2.38B -2.23B -2.03B -3.82B -263B -3.88B -26.02B -10.25B -132B -10.33B -10.11B
Logo Astellas Pharma Inc.
Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.
Employees
14,099
Date Price Change Volume
18/08/26 $15.20 -3.80% 348
17/08/26 $15.80 -2.17% 1,995
14/08/26 $16.15 +20.07% 11,200
13/08/26 $13.45 -16.20% 410
11/08/26 $16.05 +7.72% 966
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
2,310.50JPY
Average target price
2,476.43JPY
Spread / Average Target
+7.18%

Quarterly revenue - Rate of surprise